Biomarker ID | 1770 |
PMID | 30334974 |
Year | 2018 |
Biomarker | PCA3 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Blood |
Subjects | Humans |
Regulation | Upregulated in Stage T3-T4 |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 100 patients were analysed for the study. 43 patients had PCa and 57 had benign prostatic hyperplasia group (BPH) |
Senstivity | NA |
Specificity | Full Dataset: 82.5%; PSA range 4 to 10ng/mL: 100% |
AUC | Full Dataset: 0.667 (95% CI: 0.558-0.775); PSA range 4 to 10ng/mL: 0.843 (95% CI: 0.687–-0.998) |
Accuracy | NA |
Level Of Significance | NA |
Method Used | qRT-PCR |
Clinical | No |
Remarks | PCA3 cutoff: 121.2; PSA range 4 to 10ng/mL: 349.2 |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |